Tyligand Pharmaceuticals (Suzhou) Limited
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1a dose escalation/confirmation part, phase 1b dose randomization part and phase 2 dose expansion parts of TSN1611 as monotherapy or in combination with other anti-cancer therapies. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD/RP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with cetuximab and FOLFIRI, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.
Phase 1 Part of TSN1611 Monotherapy: The phase 1 part will evaluate the prespecified dose levels of TSN1611. Dose escalation will continue until up to the highest planned dose or the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Dose optimization could be performed as indicated by the emerging data. Phase 2 Part of TSN1611 Monotherapy: phase 2 part of TSN1611 monotherapy will evaluate the efficacy and safety of TSN1611 as monotherapy at the RP2D until disease progression or unacceptable toxicity in separate groups of patients with pancreatic cancer, colorect…
Subjects must meet all the following inclusion criteria to be eligible for participation in this study: * The subject fully understands the requirements of the study and voluntarily signs the ICF. * At least 18 years of age at the time of informed consent.≤ 75 years of age for Cohort B and C. * Life expectancy of 3 months or more. * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Phase 1 part (1a/1b) of Monotherapy: Subjects with histologically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation; subjects must be refractor…
TSN1611 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.
TSN1611 at the assigned dose level, orally, BID, combined with cetuximab, IV, every 2 weeks (Q2W), continuously in 28-day cycles
TSN1611 at the assigned dose level, orally, BID, combined with GnP regimen (gemcitabine and nab-paclitaxel), IV, on Day 1, 8 and 15, continuously in 28-day cycles
TSN1611 BID everyday and Patients will be administered with mFOLFOX6 on Days 1 and 2, every 2 weeks.
TSN1611 at the assigned dose level, orally, BID, combined with cetuximab and FOLFIRI (irinotecan, leucovorin, and fluorouracil), IV, every 2 weeks (Q2W), continuously in 28-day cycles,